Improving life. It’s what drives us each day. At Fluidigm, we empower our customers to reveal meaningful insights in health and disease, identify actionable markers to inform life decisions and accelerate the development of more effective therapies.
We focus on the most pressing needs in translational and clinical research, including cancer, immunology and immunotherapy.
Harnessing proprietary CyTOF® and microfluidics capabilities, we provide an unprecedented view into health and disease through our unique combination of innovative mass cytometry, tissue imaging and genomics solutions.
Researchers depend on our systems to uncover important disease pathways, find valuable new molecular biomarkers and deeply profile important cell populations down to single‑cell resolution. As a trusted partner of leading academic, government, pharmaceutical, biotechnology and plant and animal research laboratories worldwide, we strive to increase the quality of life for all.
For more information, visit us at fluidigm.com.
We focus on the most pressing needs in translational and clinical research, including cancer, immunology and immunotherapy.
Harnessing proprietary CyTOF® and microfluidics capabilities, we provide an unprecedented view into health and disease through our unique combination of innovative mass cytometry, tissue imaging and genomics solutions.
Researchers depend on our systems to uncover important disease pathways, find valuable new molecular biomarkers and deeply profile important cell populations down to single‑cell resolution. As a trusted partner of leading academic, government, pharmaceutical, biotechnology and plant and animal research laboratories worldwide, we strive to increase the quality of life for all.
For more information, visit us at fluidigm.com.
Location: United States, California, South San Francisco
Employees: 501-1000
Phone: +1 650-266-6000
Total raised: $17M
Founded date: 1999
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.01.2007 | - | $17M | - |
Mentions in press and media 17
| Date | Title | Description |
| 18.12.2025 | Bringing rapid, lab-grade diagnostics to the pond side | - |
| 04.04.2022 | Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc. | New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focu... |
| 24.01.2022 | Fluidigm scores $250M investment in microfluidics tech and a corporate makeover to boot | By the end of the first quarter of this year, Fluidigm will be nearly unrecognizable. Fluidigm plans to use the funding to grow its sales and marketing efforts, continue developing its platforms to make cell profiling and sample analysis pr... |
| 05.08.2021 | Fluidigm : Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million | Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corp... |
| 06.05.2021 | FLUIDIGM CORPORATION Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period | Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vi... |
| 25.06.2015 | Single-cell technologies advance the value of genomics | Biologists are looking to extract as much information as possible from small amounts of valuable biological material, and to understand biological responses at higher levels of resolution. The Genome Analysis Centre (TGAC) has been working ... |
| 25.06.2015 | Single-cell technologies advance the value of genomics | Single-cell technologies advance the value of genomics 25-06-2015 Biologists are looking to extract as much information as possible from small amounts of valuable biological material, and to understand biological responses at higher levels ... |
| 03.12.2012 | Genetic analysis company NanoString will use $15.3M for first launch in molecular diagnostics | The $15.3 million came from previous investors Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund, BioMed Ventures and Henri Termeer, and new investors Morgan Stanley Expansion Capital and AllianceBern... |
| 14.07.2011 | DVS SCIENCES RAISES $14.6 MILLION IN SERIES A FINANCING TO ADVANCE COMMERCIALIZATION OF NOVEL SINGLE-CELL ANALYSIS TECHNOLOGY | - |
| 10.02.2011 | Fluidigm Raises $75M in Second Chance at IPO | Share Share on Facebook Share on Twitter LinkedIn Email Reprints You know what they say about how if you don’t at first succeed, try, try again. South San Francisco-based Fluidigm said today it has completed its initial public offering, whi... |
Show more